Indianapolis, IN-December 30, 2010 - A new collaboration between a human clinical cell processing facility and tissue bank (General BioTechnology, LLC) and clinical experts in hematology/oncology, oral surgery and veterinary medicine has been launched. RenovoCyte, LLC is a cellular medicine company that is dedicated to the use of multipotent mesenchymal stromal-stem cell (MSC) therapy in the fields of veterinary and human medicine. The goal of RenovoCyte is to work hand-in-hand with veterinarians and medical doctors to establish a gold standard for the use of cell therapy in order to help treat various disease processes.
RenovoCyte originated from General Biotechnology, LLC in Indianapolis who has many years of experience in cell therapy, research, cryopreservation, cell and tissue processing, banking, manufacturing and transport. Utilizing General Biotechnology (GBT) as an in-house laboratory, RenovoCyte is capable of producing quality products and break-through technology in the field of cellular medicine. GBT and RenovoCyte share the same CEO, President and founder, Erik Woods, PhD., who leads the science behind RenovoCyte as well as the clinical team. “Our team feels strongly that each discipline on the veterinary and human clinical side can each make advancements by working together in the developing field of cellular medicine.” Woods said.
RenovoCyte’s services include cell processing, expansion, banking and cell therapy in both human and veterinary patients. Veterinary species include the dog, horse, cat and rabbit.
RenovoCyte is introducing:
1.) Wellness BankingTM of autologous MSC’s in both human and veterinary patients. The MSC’s from a healthy individual will be collected during a wellness procedure and stored until the need arises later in life. Wellness procedures in people include dental extractions in children or adults. The oral surgeon/dentist sends RenovoCyte the extracted teeth, RenovoCyte isolates the MSC’s from the dental pulp and cryopreserves them until the need arises for stem cell therapy in the future. It is a similar but more encompassing concept in veterinary medicine due to more wellness procedures being performed. In pets, RenovoCyte is banking tissue from extracted teeth (including wolf teeth) as well as from spays, neuters and declaws.
2.) Cellular therapy for intravenous MSC injections. If someone has a need for cell therapy in the immediate future, RenovoCyte can also process the stem cells and send them back to the doctor for therapy needed at that time. All available products are autologous at this time although RenovoCyte is working with the FDA on a universal donor (allogeneic) products as well.
About General BioTechnology, LLC
General BioTechnology, LLC (GBT) was established in 1997 by Indiana University School of Medicine researchers. The company is a premier cell and tissue bank and clinical cell manufacturing facility, located adjacent to the Indiana University School of Medicine campus. The company was initially based on novel technologies including methods and devices specifically related to specialized cell and tissue collection and processing and giving biological cells and tissues shelf life. GBT is registered with the Food and Drug Administration (FDA) as a Human Cell and Tissue Products (HCTP) establishment. GBT is also accredited by the American Association of Blood Banks (AABB) as an umbilical cord blood bank and is federally certified under the Clinical Laboratory Improvements Act (CLIA). GBT is also licensed in Indiana as a blood center, in New York for umbilical cord blood collection and processing, holds a New Jersey blood bank license and has a Maryland medical lab permit and tissue bank permit. More information about General BioTechnology can be found at www.gnrlbiotech.com.
